company background image
ITOS logo

iTeos Therapeutics NasdaqGM:ITOS Stock Report

Last Price

US$8.55

Market Cap

US$312.4m

7D

3.8%

1Y

-15.3%

Updated

02 Dec, 2024

Data

Company Financials +

iTeos Therapeutics, Inc.

NasdaqGM:ITOS Stock Report

Market Cap: US$312.4m

ITOS Stock Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. More details

ITOS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

iTeos Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for iTeos Therapeutics
Historical stock prices
Current Share PriceUS$8.55
52 Week HighUS$18.75
52 Week LowUS$7.54
Beta1.39
11 Month Change-2.95%
3 Month Change-48.68%
1 Year Change-15.35%
33 Year Change-73.41%
5 Year Changen/a
Change since IPO-55.12%

Recent News & Updates

Recent updates

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 15
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 15

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

Aug 11
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13
Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21
Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12
The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11
News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25
Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16
Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

iTeos Therapeutics EPS misses by $0.11

Nov 12

Shareholder Returns

ITOSUS BiotechsUS Market
7D3.8%1.6%0.6%
1Y-15.3%15.3%31.9%

Return vs Industry: ITOS underperformed the US Biotechs industry which returned 15.6% over the past year.

Return vs Market: ITOS underperformed the US Market which returned 31.4% over the past year.

Price Volatility

Is ITOS's price volatile compared to industry and market?
ITOS volatility
ITOS Average Weekly Movement10.1%
Biotechs Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: ITOS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ITOS's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011157Michel Detheuxwww.iteostherapeutics.com

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company’s lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

iTeos Therapeutics, Inc. Fundamentals Summary

How do iTeos Therapeutics's earnings and revenue compare to its market cap?
ITOS fundamental statistics
Market capUS$312.36m
Earnings (TTM)-US$121.25m
Revenue (TTM)US$35.00m

8.9x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ITOS income statement (TTM)
RevenueUS$35.00m
Cost of RevenueUS$0
Gross ProfitUS$35.00m
Other ExpensesUS$156.25m
Earnings-US$121.25m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.32
Gross Margin100.00%
Net Profit Margin-346.44%
Debt/Equity Ratio0%

How did ITOS perform over the long term?

See historical performance and comparison